In this role, O’Hara will direct the company’s U.S. and Canadian sales and customer service organizations. He will lead the sales team in providing TearScience’s advanced solutions to eye care practices to treat patients suffering from Evaporative Dry Eye disease and Meibomian Gland Dysfunction.
“Given Jeff’s broad experience in the medical device industry, he was the ideal candidate for this important role,” said Tim Willis, chief executive officer (CEO) and co-founder of TearScience. “Jeff is an excellent addition to TearScience who compliments the skills and knowledge of our leadership team. His sales team will play a critical role in delivering our breakthrough evaporative dry eye technology to the market.”
O’Hara has more than 20 years of experience in the medical device industry. Prior to joining TearScience, O’Hara was the vice president of sales for Lumenis, the world’s largest medical laser company, and managing director of U.S. sales for Solta Medical. O’Hara earned a master’s degree in business administration from James Madison University.
“This is a very exciting time to be joining TearScience,” added Jeff O’Hara. “We are on the brink of being able to help the millions of patients who suffer from Evaporative Dry Eye disease.”
In November, 2010, TearScience was recognized with an award from Southeast BIO (SEBIO) for having raised $44.5 million Series C financing, which was one of the largest med tech venture capital funding in 2010. The company’s LipiFlow® treatment device is designed for use by eye care professionals to address the root cause of Evaporative Dry Eye disease: meibomian gland dysfunction which results in a lipid deficiency of the eye’s natural tear film. TearScience will begin commercializing its devices in Europe and Canada in 2011 and is currently seeking U.S. FDA clearance for its LipiFlow treatment device.
About TearScience, Inc.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 65 percent have evaporative dry eye, which is caused by Meibomian Gland Dysfunction and a lipid deficiency of the eye’s natural tear film. TearScience’s integrated, in-office system is the first to enable eye care professionals to address a root cause of evaporative dry eye. For additional information, visit www.tearscience.com.